RU2009142513A - METHOD FOR PREVENTION OF GENITAL PROLapse IN WOMEN OF THE REPRODUCTIVE PERIOD - Google Patents
METHOD FOR PREVENTION OF GENITAL PROLapse IN WOMEN OF THE REPRODUCTIVE PERIOD Download PDFInfo
- Publication number
- RU2009142513A RU2009142513A RU2009142513/15A RU2009142513A RU2009142513A RU 2009142513 A RU2009142513 A RU 2009142513A RU 2009142513/15 A RU2009142513/15 A RU 2009142513/15A RU 2009142513 A RU2009142513 A RU 2009142513A RU 2009142513 A RU2009142513 A RU 2009142513A
- Authority
- RU
- Russia
- Prior art keywords
- content
- dexamethasone
- nmol
- months
- estradiol
- Prior art date
Links
- 206010018168 Genital prolapse Diseases 0.000 title claims abstract 3
- 230000002265 prevention Effects 0.000 title claims abstract 3
- 230000001850 reproductive effect Effects 0.000 title claims abstract 3
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 claims abstract 8
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 claims abstract 8
- 229960003957 dexamethasone Drugs 0.000 claims abstract 8
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 claims abstract 4
- 210000004899 c-terminal region Anatomy 0.000 claims abstract 4
- 229960005309 estradiol Drugs 0.000 claims abstract 4
- 229930182833 estradiol Natural products 0.000 claims abstract 4
- 230000035935 pregnancy Effects 0.000 claims abstract 4
- 229960003604 testosterone Drugs 0.000 claims abstract 4
- DBPWSSGDRRHUNT-CEGNMAFCSA-N 17α-hydroxyprogesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)C)(O)[C@@]1(C)CC2 DBPWSSGDRRHUNT-CEGNMAFCSA-N 0.000 claims abstract 2
- 229940085394 ascorbic acid 500 mg Drugs 0.000 claims abstract 2
- 239000003433 contraceptive agent Substances 0.000 claims abstract 2
- 230000002254 contraceptive effect Effects 0.000 claims abstract 2
- RWYFURDDADFSHT-RBBHPAOJSA-N diane Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1.C1=C(Cl)C2=CC(=O)[C@@H]3CC3[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(C)=O)(OC(=O)C)[C@@]1(C)CC2 RWYFURDDADFSHT-RBBHPAOJSA-N 0.000 claims abstract 2
- 230000003054 hormonal effect Effects 0.000 claims abstract 2
- 210000003205 muscle Anatomy 0.000 claims abstract 2
- 230000027758 ovulation cycle Effects 0.000 claims abstract 2
- 210000003903 pelvic floor Anatomy 0.000 claims abstract 2
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Способ профилактики пролапса гениталий у женщин репродуктивного периода, включающий проведение упражнений, укрепляющих мышцы тазового дна, отличающийся тем, что у пациентки определяют содержание С-концевых телопептидов, исследуют гормональный статус, для чего определяют содержание эстрадиола, свободного тестостерона, 17ОНпрогестерона в первую фазу менструального цикла и при нормальном уровне свободного тестостерона, нормальном или пониженном уровне эстрадиола, повышенном содержании 17ОНпрогестерона назначают пациенткам, не планирующим беременность, в течение шести месяцев Диане-35 или Жанин по контрацептивной схеме, а пациенткам, планирующим беременность, дексаметазон ежедневно вечером в течение трех месяцев, при этом при содержании 17ОНпрогестерона 3,1-4,4 нмоль/л суточная доза дексаметазона равна 0,125 мг, при содержании 17ОНпрогестерона 4,5-7,0 нмоль/л - 0,25 мг дексаметазона, при содержании 17ОНпрогестерона больше 7,0 нмоль/л - 0,5 мг дексаметазона; при содержании С-концевых телопептидов свыше 0,6 нг/мл дополнительно назначают аскорбиновую кислоту по 500 мг 3 раза в день, магнерот по 500 мг 3 раза в день в течение трех месяцев. A method for the prevention of genital prolapse in women of the reproductive period, including carrying out exercises that strengthen the muscles of the pelvic floor, characterized in that the patient determines the content of C-terminal telopeptides, investigates the hormonal status, which determines the content of estradiol, free testosterone, 17ONprogesterone in the first phase of the menstrual cycle and with a normal level of free testosterone, a normal or reduced level of estradiol, an increased content of 17 OH progesterone is prescribed to patients, I do not plan pregnancy for six months, Diane-35 or Janine according to the contraceptive scheme, and for patients planning a pregnancy, dexamethasone daily in the evening for three months, while with a content of 17 OHprogesterone 3.1-4.4 nmol / l, the daily dose of dexamethasone is 0.125 mg, with a content of 17OHprogesterone 4.5-7.0 nmol / L - 0.25 mg of dexamethasone, with a content of 17OHprogesterone greater than 7.0 nmol / L - 0.5 mg of dexamethasone; when the content of C-terminal telopeptides is more than 0.6 ng / ml, ascorbic acid 500 mg 3 times a day is additionally prescribed, magnerot 500 mg 3 times a day for three months.
Claims (1)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| RU2009142513/15A RU2427370C1 (en) | 2009-11-19 | 2009-11-19 | Method of preventing genitalia prolapse in women of reproductive period |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| RU2009142513/15A RU2427370C1 (en) | 2009-11-19 | 2009-11-19 | Method of preventing genitalia prolapse in women of reproductive period |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU2009142513A true RU2009142513A (en) | 2011-05-27 |
| RU2427370C1 RU2427370C1 (en) | 2011-08-27 |
Family
ID=44734402
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2009142513/15A RU2427370C1 (en) | 2009-11-19 | 2009-11-19 | Method of preventing genitalia prolapse in women of reproductive period |
Country Status (1)
| Country | Link |
|---|---|
| RU (1) | RU2427370C1 (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2682497C1 (en) * | 2017-10-30 | 2019-03-19 | Федеральное государственное бюджетное образовательное учреждение высшего образования Кубанский государственный медицинский университет Министерства здравоохранения Российской Федерации (ФГБОУ ВО КубГМУ Минздрава России) | Method for selecting tactics for treatment of genital prolapse in patients with undifferentiated connective tissue dysplasia |
| RU2849238C1 (en) * | 2024-03-19 | 2025-10-23 | Общество с ограниченной ответственностью Санаторий "Алтайский Замок" | Method for preventive therapy of severe genital prolapse in patients of risk group in health resort environment |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2269317C1 (en) * | 2004-05-25 | 2006-02-10 | Государственное образовательное учреждение высшего профессионального образования Московская медицинская академия им. И.М. Сеченова | Method for treating rectocele-accompanied vaginal descensus (variants) |
| WO2006034719A1 (en) * | 2004-09-28 | 2006-04-06 | Negm Sherif Mohammed Maher Ibr | Vaginal stent for prevention and treatment of vaginal vault prolapse |
| RU2310849C1 (en) * | 2006-04-27 | 2007-11-20 | Государственное образовательное учреждение высшего профессионального образования "БАШКИРСКИЙ ГОСУДАРСТВЕННЫЙ МЕДИЦИНСКИЙ УНИВЕРСИТЕТ Федерального Агентства по здравоохранению и социальному развитию" (ГОУ ВПО БГМУ РОСЗДРАВА) | Method for predicting pelvic fundus descent in female patients |
-
2009
- 2009-11-19 RU RU2009142513/15A patent/RU2427370C1/en not_active IP Right Cessation
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2682497C1 (en) * | 2017-10-30 | 2019-03-19 | Федеральное государственное бюджетное образовательное учреждение высшего образования Кубанский государственный медицинский университет Министерства здравоохранения Российской Федерации (ФГБОУ ВО КубГМУ Минздрава России) | Method for selecting tactics for treatment of genital prolapse in patients with undifferentiated connective tissue dysplasia |
| RU2849238C1 (en) * | 2024-03-19 | 2025-10-23 | Общество с ограниченной ответственностью Санаторий "Алтайский Замок" | Method for preventive therapy of severe genital prolapse in patients of risk group in health resort environment |
Also Published As
| Publication number | Publication date |
|---|---|
| RU2427370C1 (en) | 2011-08-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2009148278A (en) | The use of estriol in a low dose | |
| US9370526B2 (en) | Combination hormone replacement therapy (HRT) and melatonin to prevent and treat mammary cancer | |
| Glinoer | Clinical and biological consequences of iodine deficiency during pregnancy | |
| NZ600907A (en) | Progestin/estradiol transdermal gel | |
| NO20080824L (en) | Oral birth control with trimegestone | |
| BG62383B1 (en) | METHOD OF HORMONALIZING TREATMENT | |
| BRPI0412493A (en) | Hormonal treatment methods using contraceptive regimens with continuous estrogen administration | |
| JP2005516913A5 (en) | ||
| AR048722A1 (en) | TREATMENT OF DISRUPTION HEMORRAGY IN EXTENDED ANTI-CONCEPTIVE REGIMES | |
| BIBEN et al. | Familial hypogonadotropic eunuchoidism | |
| Daroszewska | Prevention and treatment of osteoporosis in women: an update | |
| Cucinella et al. | Sexual health and contraception in the menopause journey | |
| US9333184B2 (en) | Composition and method for affecting male and female hormone levels | |
| TW200626161A (en) | Methods of hormonal treatment utilizing ascending-dose extended cycle regimens | |
| RU2009142513A (en) | METHOD FOR PREVENTION OF GENITAL PROLapse IN WOMEN OF THE REPRODUCTIVE PERIOD | |
| RU2014151156A (en) | NALMEPHEN TO REDUCE ALCOHOL CONSUMPTION IN SPECIFIC TARGET POPULATIONS | |
| HU230920B1 (en) | Androgen pharmaceutical composition for treating depression | |
| RU2443422C2 (en) | Polyvitamin kit for women | |
| US20150031775A1 (en) | Composition and method for affecting male and female hormone levels | |
| US20040170708A1 (en) | Arrangement to enhance a woman's sexual sensitivity by a combination of phytoestrogens, L-arginine and menthol | |
| CN108703980A (en) | A kind of composition for alleviating dysmenorrhoea | |
| Wang et al. | Effects of protein and calcium supplementation on bone metabolism and thyroid function in protein and calcium deficient rabbits exposed to fluoride | |
| Hasanat et al. | Status of serum calcium and magnesium in women taking oral contraceptive | |
| Huh et al. | Retrospective multicenter study on clinical aspects in premature ovarian failure | |
| RU2009142512A (en) | METHOD FOR CONSERVATIVE TREATMENT OF WOMEN WITH PERIMENOPAUSAL PERIOD WITH GENITAL PROLAPSE |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM4A | The patent is invalid due to non-payment of fees |
Effective date: 20141120 |